Brainstorm Cell Therapeutics Inc.

1325 Avenue of the Americas, 28^th Floor

New York, NY 10019

September 4, 2024

Via EDGAR Transmission

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Re: Brainstorm Cell Therapeutics Inc. Acceleration Request for Registration Statement on Form S-3 (File No. 333-281827)

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Brainstorm Cell Therapeutics Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to September 6, 2024, at 4:30 pm Eastern Time, or as soon thereafter as practicable, unless we or outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

If you have any questions regarding this request, please contact Mayan Katz of Goodwin Procter LLP at (212) 459-7269.